Trial · NCT01774851
A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
NCT01774851, Phase 2, Terminated, Merrimack Pharmaceuticals; results first posted 2017-06-22
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach. Trials, record NCT01774851. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01774851
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
- NCT number
- NCT01774851
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 84 participants, actual
- Lead sponsor
- Merrimack Pharmaceuticals
- Conditions
- HER-2 Gene Amplification, Esophagus Cancer, Gastroesophageal Junction Cancer, Stomach Cancer
- Interventions
- MM-111, Paclitaxel, Trastuzumab
- First posted
- 2013-01-24
- Last updated
- 2017-06-22
- Results first posted
- 2017-06-22
- Limitations and caveats
- Following the recommendation of the data monitoring committee, this study was terminated prior to enrollment being completed due to lack of efficacy.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression Free Survival (PFS) | 30 months | Target and non-target lesion antitumor response and disease progression during treatment with each dosing regimen will be evaluated using the international criteria proposed by the RECIST v1.1. Disease status will be assessed every 8 weeks from the date of the first dose of any drug in a regimen. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Progression Free Survival (PFS) | 30 months | weeks | MEDIAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression Free Survival (PFS) | Control Group | 23.3 | 95% Confidence Interval 12.1 to 27.0 | weeks | |
| Progression Free Survival (PFS) | Experimental Group | 9.6 | 95% Confidence Interval 8.0 to 15.7 | weeks |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Control Group | 42 | |
| Overall Study | STARTED | Experimental Group | 42 | |
| Overall Study | COMPLETED | Control Group | 42 | |
| Overall Study | COMPLETED | Experimental Group | 42 | |
| Overall Study | NOT COMPLETED | Control Group | 0 | |
| Overall Study | NOT COMPLETED | Experimental Group | 0 |
Source ClinicalTrials.gov
Adverse events186
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhoea | Gastrointestinal disorders | Control Group | 12 | 42 | 12 |
| other | Diarrhoea | Gastrointestinal disorders | Experimental Group | 22 | 42 | 22 |
| other | Nausea | Gastrointestinal disorders | Control Group | 11 | 42 | 11 |
| other | Nausea | Gastrointestinal disorders | Experimental Group | 11 | 42 | 11 |
| other | Constipation | Gastrointestinal disorders | Control Group | 7 | 42 | 7 |
| other | Constipation | Gastrointestinal disorders | Experimental Group | 6 | 42 | 6 |
| other | Vomiting | Gastrointestinal disorders | Control Group | 5 | 42 | 5 |
| other | Vomiting | Gastrointestinal disorders | Experimental Group | 13 | 42 | 13 |
| other | Abdominal pain upper | Gastrointestinal disorders | Control Group | 7 | 42 | 7 |
| other | Abdominal pain upper | Gastrointestinal disorders | Experimental Group | 2 | 42 | 2 |
1 to 10 of 186Source ClinicalTrials.gov
See all 186 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Control Group | 18 | 42 |
| Total, all-cause mortality | Experimental Group | 11 | 42 |
| Total, other adverse events | Control Group | 26 | 42 |
| Total, other adverse events | Experimental Group | 39 | 42 |
| Total, serious adverse events | Control Group | 16 | 42 |
| Total, serious adverse events | Experimental Group | 19 | 42 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Experimental Group vs Control Group: deaths from any cause | Trial comparisons |
| Experimental Group vs Control Group: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01774851
GET https://conductscience.org/api/trials/v1/NCT01774851/events?page=2